U.S. attorneys general urge the FDA to combat counterfeit versions of weight loss drugs developed by Eli Lilly (LLY) and Novo Nordisk (NVO). Read more here.

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. | Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight.

Eli Lilly is airing an ad during the Academy Awards urging customers to adopt a health skepticism when marketed drug brands that are not FDA-approved.

Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells

The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs. All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October,

Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest. Eli Lilly, the manufacturer of Zepbound, which is FDA-approved to help treat obesity and obesity with obstructive sleep apnea,

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday. The update about the popular semaglutide injections from drug manufacturer Novo Nordisk follows just two months after the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro from competitor Eli Lilly had also ended.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print campaign urging people to “Check Before You Inj

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, the growing measles outbreak in Texas,

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its official shortage list arbitrarily and without warning.